Project Grant R01HL181902
Award Date
7/20/25
Completion Date
6/30/29
Dollars Obligated
$622K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
The federal Project Grant award of $620,371, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to determine the voltage-sensing domain (VSD) dynamics of cardiac ion channels from the CNBD family, which play a pivotal role in regulating the electrical properties of the heart. The overarching objective is to leverage advanced biophysical techniques, including patch-clamp fluorometry, transition...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Johns Hopkins University provides $1,402,988.66 in funding from September 1, 2024 to July 31, 2028. The project aims to investigate the role of protein kinase G (PKG) and the ubiquitin ligase CHIP in enhancing the degradation of mutant transthyretin to attenuate cardiac amyloidosis. Key objectives include: Testing if PKG stimulation or expression of a CHIP...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $633,720 to The Washington University to conduct research on protein arginylation and its impact on cardiovascular health and development. The key objectives are to: Develop a chemical proteomics platform to comprehensively identify proteins that undergo arginylation in cardiac cells and tissues. This will involve mapping the "arginylome" and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $121,773 to the University of Arizona to investigate the role of the serum/glucocorticoid regulated kinase 1 (SGK1) in driving pathological cardiac hypertrophy. The research aims to determine if SGK1 is required for the development of cardiac hypertrophy and if impairing its degradation through the endoplasmic reticulum-associated degradation (ERAD)...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award, totaling $2,158,428 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at investigating the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in mediating hypertension and vascular remodeling. The award supports three specific aims: 1) Studying the involvement of PKM2 activation in vascular smooth muscle cells (VSMCs) in hypertension and vascular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
The federal Project Grant award R01HL177433, funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports a research project to investigate the structural dynamics and regulatory mechanisms of the Atrial Natriuretic Peptide Receptor (ANPR or GC-A) over a period of 4 years from December 2024 to November 2028. The $535,213 grant awarded to Weill Medical College of Cornell University aims to: 1) delineate the structural changes in GC-A upon...